Brief: FDA Approves Genentech’S Tecentriq For Adjuvant Muscle-Invasive Bladder Cancer With Ctdna-Guided Treatment
15/05/2026 20:57
May 15 (Reuters) - FDA: FDA APPROVES GENENTECH’S TECENTRIQ FOR ADJUVANT MUSCLE-INVASIVE BLADDER CANCER WITH CTDNA-GUIDED TREATMENT Source text: ID:nBwbChSJ2a Further company coverage: ROPC.S ((Reuters.Briefs@thomsonreuters.com;))
Recent news on Roche Holding AG
See all newsTable: Swiss trade surplus at CHF 6.11 bln in May
Brief: Roche - FDA Accepts Supplemental Biologics License Application For Lunsumio And Polivy Combination
Swiss stocks - Factors to watch on June 18
FDA approves first generic version of Roche's flu drug
Brief: FDA Approves First Single-Dose Generic Treatment For Influenza